Dr Federica Raguseo is a chemical biologist working in drug discovery at the GSK–Francis Crick Institute, where she builds high-throughput screening platforms to identify novel therapeutic targets. She holds a PhD from Imperial College London, and has published nine peer-reviewed papers including a first-author study in Nature Communications. Outside the lab, Federica is the founder of ThatScienceIllustrator, a science communication platform with over 50,000 followers and 1M+ monthly reach, and has collaborated with Microsoft UK, the Francis Crick Institute and Great Ormond Street Hospital to make science accessible to wider audiences. She has been recognised on the Nova 111 List for Healthcare & Life Sciences

Dr. Friederike Pfeiffer did her Bachelor’s in Biology in Germany and her Master’s degree in the USA at the University of New York at Stony Brook (SUNY), funded by the DAAD. Afterwards, she did her PhD Thesis at the University of Tübingen in animal physiology, supervised by Professor Hartwig Wolburg. Since then, she has had several international experiences, such as at Theodor-Kocher Institute, Bern, Switzerland; at INSERM, Paris, France; at CIN, Tübingen, Germany; and at the University of Connecticut, USA, as part of the outgoing phase of a Marie-Sklodowska-Curie Fellowship. Besides being invited several times as a speaker, during the last 10 years, she has also been mentoring undergraduate and graduate students. Nowadays, she works as an Academic Associate/Group Leader at the Department of Neurophysiology at the University of Tübingen, in the field of neuroscience.

Prof. Dr. Richard Chahwan joins DLSM as Full Professor, leading a research program at the intersection of cancer immunology and genome editing (www.chahwanlab.com). His group decodes the fundamental mechanisms of immune–tumor crosstalk to drive two complimentary clinical streams: harnessing extracellular vesicles (EVs) for next-generation diagnostics and leveraging antibody diversification to speed the development of immunotherapeutics. Formerly at the University of Zurich, Richard is a dedicated scientist-entrepreneur, serving as co-founder of EVIIVE AG (www.eviive.ch) and advisory board member at Ymmunobio (www.ymmunobio.com). His mission at the University of Luxembourg is to continue translating cancer immunology concepts into actionable and impactful medical solutions.